Cargando…

Management of advanced ovarian cancer in Spain: an expert Delphi consensus

BACKGROUND: To determine the state of current practice and to reach a consensus on recommendations for the management of advanced ovarian cancer using a Delphi survey with a group of Spanish gynecologists and medical oncologists specially dedicated to gynecological tumors. METHODS: The questionnaire...

Descripción completa

Detalles Bibliográficos
Autores principales: Redondo, Andres, Oaknin, Ana, Rubio, Maria Jesus, Barretina-Ginesta, Maria-Pilar, de Juan, Ana, Manso, Luis, Romero, Ignacio, Martin-Lorente, Cristina, Poveda, Andres, Gonzalez-Martin, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157411/
https://www.ncbi.nlm.nih.gov/pubmed/34039386
http://dx.doi.org/10.1186/s13048-021-00816-x
_version_ 1783699677616537600
author Redondo, Andres
Oaknin, Ana
Rubio, Maria Jesus
Barretina-Ginesta, Maria-Pilar
de Juan, Ana
Manso, Luis
Romero, Ignacio
Martin-Lorente, Cristina
Poveda, Andres
Gonzalez-Martin, Antonio
author_facet Redondo, Andres
Oaknin, Ana
Rubio, Maria Jesus
Barretina-Ginesta, Maria-Pilar
de Juan, Ana
Manso, Luis
Romero, Ignacio
Martin-Lorente, Cristina
Poveda, Andres
Gonzalez-Martin, Antonio
author_sort Redondo, Andres
collection PubMed
description BACKGROUND: To determine the state of current practice and to reach a consensus on recommendations for the management of advanced ovarian cancer using a Delphi survey with a group of Spanish gynecologists and medical oncologists specially dedicated to gynecological tumors. METHODS: The questionnaire was developed by the byline authors. All questions but one were answered using a 9-item Likert-like scale with three types of answers: frequency, relevance and agreement. We performed two rounds between December 2018 and July 2019. A consensus was considered reached when at least 75% of the answers were located within three consecutive points of the Likert scale. RESULTS: In the first round, 32 oncologists and gynecologists were invited to participate, and 31 (96.9%) completed the online questionnaire. In the second round, 27 (87.1%) completed the online questionnaire. The results for the questions on first-line management of advanced disease, treatment of patients with recurrent disease for whom platinum might be the best option, and treatment of patients with recurrent disease for whom platinum might not be the best option are presented. CONCLUSIONS: This survey shows a snapshot of current recommendations by this selected group of physicians. Although the majority of the agreements and recommendations are aligned with the recently published ESMO-ESGO consensus, there are some discrepancies that can be explained by differences in the interpretation of certain clinical trials, reimbursement or accessibility issues.
format Online
Article
Text
id pubmed-8157411
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81574112021-05-28 Management of advanced ovarian cancer in Spain: an expert Delphi consensus Redondo, Andres Oaknin, Ana Rubio, Maria Jesus Barretina-Ginesta, Maria-Pilar de Juan, Ana Manso, Luis Romero, Ignacio Martin-Lorente, Cristina Poveda, Andres Gonzalez-Martin, Antonio J Ovarian Res Research BACKGROUND: To determine the state of current practice and to reach a consensus on recommendations for the management of advanced ovarian cancer using a Delphi survey with a group of Spanish gynecologists and medical oncologists specially dedicated to gynecological tumors. METHODS: The questionnaire was developed by the byline authors. All questions but one were answered using a 9-item Likert-like scale with three types of answers: frequency, relevance and agreement. We performed two rounds between December 2018 and July 2019. A consensus was considered reached when at least 75% of the answers were located within three consecutive points of the Likert scale. RESULTS: In the first round, 32 oncologists and gynecologists were invited to participate, and 31 (96.9%) completed the online questionnaire. In the second round, 27 (87.1%) completed the online questionnaire. The results for the questions on first-line management of advanced disease, treatment of patients with recurrent disease for whom platinum might be the best option, and treatment of patients with recurrent disease for whom platinum might not be the best option are presented. CONCLUSIONS: This survey shows a snapshot of current recommendations by this selected group of physicians. Although the majority of the agreements and recommendations are aligned with the recently published ESMO-ESGO consensus, there are some discrepancies that can be explained by differences in the interpretation of certain clinical trials, reimbursement or accessibility issues. BioMed Central 2021-05-26 /pmc/articles/PMC8157411/ /pubmed/34039386 http://dx.doi.org/10.1186/s13048-021-00816-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Redondo, Andres
Oaknin, Ana
Rubio, Maria Jesus
Barretina-Ginesta, Maria-Pilar
de Juan, Ana
Manso, Luis
Romero, Ignacio
Martin-Lorente, Cristina
Poveda, Andres
Gonzalez-Martin, Antonio
Management of advanced ovarian cancer in Spain: an expert Delphi consensus
title Management of advanced ovarian cancer in Spain: an expert Delphi consensus
title_full Management of advanced ovarian cancer in Spain: an expert Delphi consensus
title_fullStr Management of advanced ovarian cancer in Spain: an expert Delphi consensus
title_full_unstemmed Management of advanced ovarian cancer in Spain: an expert Delphi consensus
title_short Management of advanced ovarian cancer in Spain: an expert Delphi consensus
title_sort management of advanced ovarian cancer in spain: an expert delphi consensus
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157411/
https://www.ncbi.nlm.nih.gov/pubmed/34039386
http://dx.doi.org/10.1186/s13048-021-00816-x
work_keys_str_mv AT redondoandres managementofadvancedovariancancerinspainanexpertdelphiconsensus
AT oakninana managementofadvancedovariancancerinspainanexpertdelphiconsensus
AT rubiomariajesus managementofadvancedovariancancerinspainanexpertdelphiconsensus
AT barretinaginestamariapilar managementofadvancedovariancancerinspainanexpertdelphiconsensus
AT dejuanana managementofadvancedovariancancerinspainanexpertdelphiconsensus
AT mansoluis managementofadvancedovariancancerinspainanexpertdelphiconsensus
AT romeroignacio managementofadvancedovariancancerinspainanexpertdelphiconsensus
AT martinlorentecristina managementofadvancedovariancancerinspainanexpertdelphiconsensus
AT povedaandres managementofadvancedovariancancerinspainanexpertdelphiconsensus
AT gonzalezmartinantonio managementofadvancedovariancancerinspainanexpertdelphiconsensus